Thiruvananthapuram: Health Minister Veena George has said that the Zero Prevalence Survey conducted by the state has shown high zero positivity. Of the 4429 samples tested and analyzed in the age group of 18 years and above, 3659 were positive. Zero prevalence in this category is 82.6%. This indicates that the level of antibody is high in the age group of 18 years and above. It can be caused by a natural infection or by the Kovid vaccine. Given the high level of Kovid vaccination coverage in Kerala, the significant contribution of Kovid vaccination in the state may be due to the spread of this level of antibodies.
Of the 2274 samples analyzed in the 18–49 age group of pregnant women, 1487 were positive. The seroprevalence in this category is 65.4%. Seroprevalence is relatively low in pregnant women. The reasons for this are the more protective covid appropriate behavior that women may receive during pregnancy, and the delayed covid immunization of pregnant women.
Of the 1459 samples tested and analyzed in the category of children aged 5 to 17 years, 586 were positive. The seroprevalence in this category is 40.2%. This is much lower than in the age group of 18 years and above and in the category of pregnant women. The use of Kovid vaccine in children is not approved in India. In addition, exposure to Kovid-related components is low in this category. It causes low seroprevalence in children.
Of the 1521 samples tested and analyzed in the tribal population aged 18 years and above, 1189 were positive. The seroprevalence in this category is 78.2%. The seroprevalence of the tribal population is slightly lower than the seroprevalence of those aged 18 years and above. Indigenous peoples are less likely to be infected with the virus due to the rural nature and population density of their habitat. Immunizations can increase seroprevalence in this category.
Of the 1476 samples tested and analyzed in the coastal segment aged 18 years and above, 1294 were positive. The seroprevalence in this category is 87.7%. The seroprevalence of coastal communities is higher than that of seroprevalence in the age group of 18 years and above. It is associated with more clusters and cases being reported from these areas during the epidemic.
Of the 1706 samples tested and analyzed in urban slum dwellers aged 18 years and above, 1455 were positive. The seroprevalence in this category is 85.3%. Seroprevalence in this category is higher than that in seroprevalence in the age group of 18 years and above. The high population density in such areas leads to high levels of spread.
The third phase of the Zero Survey was conducted in September 2021. There were six main goals. Find out the prevalence of the disease in everyone aged 18 and above, detect Kovid 19 infection in pregnant women between the ages of 18 and 49 who are hospitalized, detect Kovid infection in children aged 5 to 17 years, detect the percentage of Kovid infected adults in tribal areas (above 18 years) and in the percentage of adults in coastal areas The goals were to determine the percentage of adults infected and the percentage of adults living in urban slums.
The study also had three objectives: to identify the factors that contribute to the spread of the disease in the study, to determine the risk of infection in those who have been vaccinated, and to determine how many of those infected and how many of those infected have died.
Seroprevalence is calculated on the basis of IgG SARS CoV-2 S1 RBD antibody (anti-spike antibody) and IgG SARS CoV-2 nucleocapsid antibody (anti-nucleocapsid antibody). Antispyb antibodies are produced in a person during a natural infection caused by the Kovid 19 virus (SARS CoV-2) or any available Kovid vaccine. Antinucleocapsid antibodies are produced in an individual when there is a natural infection or when the cow is vaccinated with the exception of the cochlear vaccine.
Zero prevalence is determined based on the positivity of an individual based on the presence of either of the 2 types of antibodies. This is similar to the fourth phase survey conducted by the Indian Council of Medical Research (ICMR). 13,198 samples were analyzed for IgG SARS CoV-2 S1 RBD antibody in 6 categories. 13,339 samples were tested and analyzed for the presence of IgG SARS CoV-2 nucleocapsid antibody. 12865 samples were analyzed to calculate zero prevalence based on the availability of both types of test results.
.
